The UAB Hazelrig-Salter Radiation Oncology Center and the Kirklin Clinic at Acton Road will obtain their ASTRO-APEx accreditation until September 2027.

The O’Neal Comprehensive Cancer Center at UAB is recruiting Alabama women who have never had breast cancer for the study, to test a personalized approach to breast cancer screening.

Physicians in the O’Neal Comprehensive Cancer Center at UAB are advancing the field of thyroid care with cutting-edge, patient-specific procedures and collaborative research investigations.

Ovarian cancer is known as the “silent killer” due to the difficulty in early detection because most women do not have any early symptoms.

IN8bio has opened a new Birmingham facility, a 10,000-square-foot advanced research and development laboratory in the Martin Biscuit Building at Pepper Place.

A first-of-its-kind endowment from art patrons Lydia Cheney and Jim Sokol will ensure the well-being of UAB’s Abroms-Engel Institute for the Visual Arts and contemporary art for years to come.

As one of only five universities selected, UAB joins the NIH’s first major program to address how structural and institutional factors of persistent poverty relate to cancer.

UAB is partnering with the American Cancer Society and ADPH to launch a statewide action plan to eliminate cervical cancer.

Dating since October of 2021, UAB juniors Burnett and Criswell placed first in their respective research categories at the 100th annual Alabama Academy of Science Conference.

Even when at odds with his health, Matalon continued his academic excellence and service to the field of lung disease research.

An overabundance of mast cells, which are important components of the immune system and are produced in the bone marrow, can lead to a variety of health issues.

At the O’Neal Comprehensive Cancer Center, a clinical trial and a collaborative care team tackle an aggressive form of T-cell lymphoma in a patient—now a survivor—from Montgomery.

The funding will support 24 research projects at seven institutions in Alabama.

New screening guidelines and improvements in diagnostics and treatment have improved outcomes in lung cancer.

UAB’s research and reputation land it among the top institutions in the world.

The clinically approved drug ruxolitinib suppressed a mouse model of melanoma that is resistant to immune checkpoint blockers.

UAB researchers have discovered a new way to treat melanoma by targeting CDC7 with EZH2 or BRPF1/2/3 inhibitors.

The deciphering of a new signaling cascade sheds light on how mutations in metabolism cause normal cells to become cancerous.

The researchers found that ARID1A-deficient bladder cancers are sensitive to combination therapies with the EZH2 inhibitor and inhibitors of PI3K, in a synergistic manner.

U.S. News & World report named UAB Hospital as the best hospital in Alabama.